80 related articles for article (PubMed ID: 28635318)
1. What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?
Yao D; Liu J; Ouyang L
Future Med Chem; 2017 Jun; 9(9):839-842. PubMed ID: 28635318
[No Abstract] [Full Text] [Related]
2. Design and characterization of bivalent BET inhibitors.
Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
[TBL] [Abstract][Full Text] [Related]
3. An Overview on Small Molecule Inhibitors of BRD4.
Huang W; Zheng X; Yang Y; Wang X; Shen Z
Mini Rev Med Chem; 2016; 16(17):1403-1414. PubMed ID: 27290915
[TBL] [Abstract][Full Text] [Related]
4. Phthalimide-Conjugated Ligands Promote Selective Protein Destabilization.
Cancer Discov; 2015 Jul; 5(7):691. PubMed ID: 26045013
[TBL] [Abstract][Full Text] [Related]
5. Disrupting the reader of histone language.
Oliver SS; Denu JM
Angew Chem Int Ed Engl; 2011 Jun; 50(26):5801-3. PubMed ID: 21618372
[No Abstract] [Full Text] [Related]
6. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
[TBL] [Abstract][Full Text] [Related]
7. Cancer research: Open ambition.
Maxmen A
Nature; 2012 Aug; 488(7410):148-50. PubMed ID: 22874946
[No Abstract] [Full Text] [Related]
8. Cancer: Bet on drug resistance.
Settleman J
Nature; 2016 Jan; 529(7586):289-90. PubMed ID: 26735017
[No Abstract] [Full Text] [Related]
9. BRD4: a BET(ter) target for the treatment of AML?
Valent P; Zuber J
Cell Cycle; 2014; 13(5):689-90. PubMed ID: 24526121
[No Abstract] [Full Text] [Related]
10. Heart failure: BRD4 inhibition slows HF progression.
Ummarino D
Nat Rev Cardiol; 2017 Jul; 14(7):382-383. PubMed ID: 28569271
[No Abstract] [Full Text] [Related]
11. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.
Qi J
Cold Spring Harb Perspect Biol; 2014 Dec; 6(12):a018663. PubMed ID: 25452384
[TBL] [Abstract][Full Text] [Related]
12. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
[TBL] [Abstract][Full Text] [Related]
13. Targeting the BET family for the treatment of leukemia.
Lucas X; Günther S
Epigenomics; 2014 Apr; 6(2):153-5. PubMed ID: 24811781
[No Abstract] [Full Text] [Related]
14. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
[TBL] [Abstract][Full Text] [Related]
15. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
16. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
17. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
Amemiya S; Yamaguchi T; Hashimoto Y; Noguchi-Yachide T
Bioorg Med Chem; 2017 Jul; 25(14):3677-3684. PubMed ID: 28549889
[TBL] [Abstract][Full Text] [Related]
19. 4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
Schäker-Hübner L; Warstat R; Ahlert H; Mishra P; Kraft FB; Schliehe-Diecks J; Schöler A; Borkhardt A; Breit B; Bhatia S; Hügle M; Günther S; Hansen FK
J Med Chem; 2021 Oct; 64(19):14620-14646. PubMed ID: 34582215
[TBL] [Abstract][Full Text] [Related]
20. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.
Chan KH; Zengerle M; Testa A; Ciulli A
J Med Chem; 2018 Jan; 61(2):504-513. PubMed ID: 28595007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
